January 29, 2018
A Joint Statement from the pan-Canadian Pharmaceutical Alliance and the Canadian Generic Pharmaceutical Association
On behalf of participating federal, provincial, and territorial public drug plans, the pan-Canadian Pharmaceutical Alliance (pCPA), with the Canadian Generic Pharmaceutical Association (CGPA) have jointly developed a new five-year initiative that will provide significant savings for all Canadians who use prescription generic drugs, participating public drug plans, and employee drug plans.
December 18, 2017
Toronto, December 18, 2017 – The following is a statement by Jim Keon, President of the Canadian Generic Pharmaceutical Association (CGPA), regarding the passing of Dr. Barry and Honey Sherman.
November 14, 2017
New Report: Canadian R&D-to-Sales Ratio for Brand-Name Drug Companies Less than Half of 10% Commitment
Toronto, November 14, 2017 – Brand-name drug companies’ research and development spending as a percentage of sales in Canada is less than half of the 10% the industry committed to when their periods of market exclusivity were increased in 1987, according to the most recent annual report from the federal government’s Patented Medicine Prices Review Board (PMPRB).